Search results for "platelet"

showing 10 items of 786 documents

Exploring Inflammatory Status in Febrile Seizures Associated with Urinary Tract Infections: A Two-Step Cluster Approach

2021

Background: Urinary tract infections (UTIs) are considered common facilitating factors, along with other infections, in triggering febrile seizures (FS). The main purpose of our study was to identify specific inflammatory patterns of UTI cases from other infections in a specific cluster, using a combination of inflammatory biomarkers to differentiate UTIs from other bacterial diseases triggering FS. Method: This prospective study included a number of 136 patients with 197 distinct FS events, from patients hospitalized in the Pediatric Clinical Hospital Sibiu, among which 10.2% were diagnosed with UTIs. Results: In one-third of the patients with UTIs (20 cases), the symptoms were limited to …

medicine.medical_specialtyUrinary systemTwo stepNeurosciences. Biological psychiatry. NeuropsychiatryUrinecut-off valuesurologic and male genital diseasesGastroenterologyArticleInternal medicineMedicinefebrile seizuresMean platelet volumeProspective cohort studyinflammatory biomarkersbiologybusiness.industryGeneral NeurosciencePlatelet Distribution WidthC-reactive proteinInflammatory biomarkersfemale genital diseases and pregnancy complicationsurine leukocyte and nitrite stick testlaboratory databiology.proteinurinary tract infectionsbusinessCRPRC321-571cluster analysisBrain Sciences
researchProduct

Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study

1999

The HAPARG Study (haemostatic parameters as risk factors in healthy volunteers) was performed in a subset of volunteers taking part in the MARISK Study (Mainzer Risikoindikatoren Studie fur die koronare Herzkrankheit) sponsored by the German Ministry of Research and started in 1984. A previous study (Yamanishi et al., Thromb Haemostas 1985;54:539-543) had shown that spontaneously enhanced platelet aggregation as measured with the PAT-III-test and higher fibrinogen concentrations are significant risk factors for new vascular occlusions in diabetic patients. It was the aim of the HAPARG Study to establish whether spontaneous platelet aggregation and other hemostatic variables are independent …

medicine.medical_specialtyVascular diseasebusiness.industryOdds ratiomedicine.diseaseElevated diastolic blood pressureSurgeryBlood pressureInternal medicineDiabetes mellitusmedicineCardiologySpontaneous platelet aggregationRisk factorCardiology and Cardiovascular MedicineProspective cohort studybusinessAtherosclerosis
researchProduct

Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients

1982

SummaryIn 13 type II hyperlipidemics (10 males and 3 females; mean age 50.2 ± 10.6 years), in 10 type IV hyperlipidemics (7 males and 3 females; mean age 51 ± 13.3 years) and in 23 healthy age-and sex-matched controls, the following parameters were measured: plasma cholesterol; plasma TG; plasma C-HDL; VLDL, separated in a preparative ultracentrifuge; C-LDL; Apo B, with immunoelectrophoretic method; platelet sensitivity to prostacyclin; TXB2 formation in PRP; TXB2 in serum.This study provides evidence for: 1. Reduced platelet sensitivity to prostacyclin, more evident in type II hyperlipidemia that provides an additional mechanism involved in increased platelet aggregation found in type II h…

medicine.medical_specialtyVery low-density lipoproteinApolipoprotein BbiologyChemistryProstacyclinStimulationHematologyThromboxane ProductionEndocrinologyThrombinInternal medicinemedicinebiology.proteinlipids (amino acids peptides and proteins)PlateletThromboxane-A synthasemedicine.drug
researchProduct

Antivitamin K Drugs in Stroke Prevention

2014

Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective …

medicine.medical_specialtyVitamin KSettore MED/09 - Medicina InternaAppropriate useInternal medicinemedicineAnimalsHumanscardiovascular diseasesRandomized Controlled Trials as TopicPharmacologySupraventricular arrhythmiabusiness.industryPatient choiceStandard treatmentAnticoagulantsVKAs Stroke preventionAtrial fibrillationmedicine.diseaseStrokeIschemic Attack TransientStroke preventionCardiologyCerebral ischaemiaCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsDiscovery and development of direct thrombin inhibitorsCurrent Vascular Pharmacology
researchProduct

The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Pl…

2021

Background: The ISTH Bleeding Assessment Tool (ISTH-BAT) has been validated for clinical screening of suspected von Willebrand disease (VWD) and for bleeding prediction. Recently it has been validated for subjects with inherited platelet disorders (IPD) (BAT-VAL study). Objectives: To determine whether the ISTH-BAT bleeding score (BS) predicts subsequent bleeding events requiring treatment in IPD patients. Methods: Patients with IPD, type 1 VWD (VWD-1) and age- and sex-matched healthy controls enrolled in the BAT-VAL study were prospectively followed-up for 2 years and bleeding episodes requiring treatment were recorded. Results: Of the 1098 subjects initially enrolled, 955 were followed-up…

medicine.medical_specialtyanimal structuresmild&#8208Platelet Function TestsPlatelet disorderinherited platelet disorderHemorrhage030204 cardiovascular system & hematologyHemorrhage/diagnosis03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactorVon Willebrand diseaseMedicineHumansPlateletBleeding prediction Bleeding score Blood platelet disorders Child Communication Hemorrhage Humans Inherited platelet disorders Mild-moderate bleeding disorders Platelet Function Tests von Willebrand diseases von Willebrand FactorChildBlood Platelet Disordersddc:616mild-moderate bleeding disordersbiologybusiness.industrymild-moderate bleeding disorderIncidence (epidemiology)CommunicationSettore MED/09 - MEDICINA INTERNAbleeding predictionvon Willebrand Diseases/diagnosis/genetics[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologymedicine.diseaseBlood Platelet Disorders/diagnosis/genetics3. Good healthbleeding scoreInstitutional repositoryvon Willebrand Diseasesmoderate bleeding disordersinherited platelet disordersQuartilebiology.proteinBlood Platelet Disordersvon Willebrand diseasebusinessJournal of thrombosis and haemostasis : JTHREFERENCES
researchProduct

Thromboxane formation by platelets and platelet sensitivity to prostacyclin in patients with acute myocardial infarction

1981

medicine.medical_specialtybiologyThromboxanebusiness.industryProstacyclinHematologymedicine.diseaseInternal medicinemedicineCardiologybiology.proteinPlateletIn patientMyocardial infarctionThromboxane-A synthasebusinessmedicine.drug
researchProduct

Fibrinogen and von Willebrand factor in type II diabetes mellitus

1992

A hypercoagulable state may contribute to the formation of early vascular lesions in diabetes. The von Willebrand factor is required for the attachment of platelets to the subendothelium; fibrinogen is required for platelet aggregation. This study was designed to assess in type II diabetic patients plasma levels of fibrinogen and von Willebrand factor to see if these variables are associated with platelet aggregation responses to adenosine diphosphate (ADP). Fibrinogen and the von Willebrand factor were significantly increased in diabetics but only fibrinogen was significantly related to platelet aggregation for ADP. Strict metabolic control does not reduce the increased concentrations of t…

medicine.medical_specialtybiologybusiness.industryEndocrinology Diabetes and MetabolismGeneral MedicineFibrinogenmedicine.diseaseAdenosine diphosphatechemistry.chemical_compoundEndocrinologyEndocrinologychemistryVon Willebrand factorInternal medicineMetabolic control analysisDiabetes mellitusInternal Medicinebiology.proteinMedicinePlateletRisk factorbusinessmedicine.drugMacrovascular diseaseActa Diabetologica
researchProduct

Patterns of changes of anti‐ADAMTS13 after plasma exchange

2006

An enzyme-linked immunosorbent assay (ELISA) has recently been developed to detect antibodies against the von Willebrand factor-cleaving protease ADAMTS13 in patients with thrombotic thrombocytopenic purpura (TTP). The ELISA is based on incubation of plasma with immobilized recombinant ADAMTS13 followed by visualization of IgG and IgM antibodies by means of secondary enzyme-labeled antibodies [1]. In a recent study, anti-ADAMTS13 IgG antibodies were detected in most patients with TTP (97%) characterized by severe ADAMTS13 deficiency (< 10% of normal) [1]. The ELISA was more sensitive than the standard inhibitor assay based upon ADAMTS13 neutralizing activity, which gave positive results in …

medicine.medical_specialtybiologybusiness.industryThrombotic thrombocytopenic purpuraAntibody titerHematologymedicine.diseaseGastroenterologyADAMTS13Immunoglobulin GTiterhemic and lymphatic diseasesInternal medicineImmunologymedicinebiology.proteinPlateletAntibodybusinessIncubationJournal of Thrombosis and Haemostasis
researchProduct

015: Relation between platelet activation and inflammation indexes measured on admission and new onset atrial fibrillation in patients with acute myo…

2013

ObjectivePlatelet activation is present in atrial fibrillation (AF), but there is some debate whether this is due to AF itself and/or to underlying cardiovascular diseases. We aim to determine the association between a marker of platelet reactivity (mean platelet volume (MPV)) and systemic inflammation (CRP) measured on admission, and new onset episode of AF in patients with MI.Patients and methodsProspective cohort of 4994 consecutive patients with AMI. Patients with paroxysmal or persistent AF were excluded.Results426 (8.5%) patients were diagnosed with a new onset of AF during the in-hospital-stay (mean stay 3±2 days). These patients were older (75 vs 65, p<0.001), predominantly male, an…

medicine.medical_specialtybusiness.industryAtrial fibrillationInflammationSystemic inflammationmedicine.diseaseInternal medicinemedicineCardiologyIn patientMyocardial infarctionPlatelet activationmedicine.symptomMean platelet volumeCardiology and Cardiovascular MedicineProspective cohort studybusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

2019

Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy that involves abnormal processing of von-Willebrand factor (vWF) and results in multiple organ dysfunction. Although aTTP remains a very unpredictable disease, risk factors for death include older age, lactate dehydrogenase (LDH) levels &gt;10x the upper limit of normal (ULN), and cerebral involvement (i.e., the French severity score) (Benhamou et al. Haematologica 2012;97:1181-1186). In addition, raised cardiac troponin-I (cTnI) levels of &gt;2.5 µg/L have also been linked with a higher risk of mortality or refractoriness (Benhamou et al. J Thromb Haemost 2015;1…

medicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyBiochemistryTherapeutic immunosuppressionDisease severityInternal medicineSeverity of illnessmedicinePlatelet Count measurementThrombotic MicroangiopathiesIn patientCaplacizumabbusinessBlood
researchProduct